New Approaches to Antibiotic Use and Review of Recently Approved Antimicrobial Agents

Abstract

Antimicrobial drug-resistance continues to force adaptation in our clinical practice. We explore new evidence regarding adjunctive antibiotic therapy for skin and soft tissue abscesses as well as duration of therapy for intra-abdominal abscesses. As new evidence refines optimal practice, it is essential to support clinicians in adopting practice patterns concordant with evidence-based guidelines. We review a simple approach that can 'nudge' clinicians towards concordant practices. Finally, the use of novel antimicrobials will play an increasingly important role in contemporary therapy. We review five new antimicrobials recently FDA-approved for use in drug-resistant infections: dalbavancin, oritavancin, ceftaroline, ceftolozane-tazobactam, and ceftazidime-avibactam.

Keywords: Antimicrobial resistance; Ceftaroline fosamil; Ceftazidime-avibactam; Ceftolozane-tazobactam; Dalbavancin; Intraabdominal abscess; Oritavancin; Soft tissue abscess.